📰 Solid Tumors News
Page 38 - Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumors. Real-time updates on events, politics, business and more.
January 25, 2023
An award-winning genomic assay for measuring HER2 mRNA expression could help predict treatment responses in advanced HER2+ breast cancer and ultimately guide clinical decision-making, suggests study.
January 22, 2023
/PRNewswire/ -- The "ADC Contract Manufacturing Market by Phase of Development, Scale of Operation, Type of Component Manufacturing, Target Indications, Type...
January 20, 2023
QINLOCK® (ripretinib) now Medsafe approved for GIST patients in NZ QINLOCK now being considered by PHARMAC for reimbursement Data from the INVICTUS Phase 3 study shows QINLOCK reduces risk of disease progression or death by 85%1, 2 SINGAPORE and AUCKLAND, New Zealand, Jan. 20, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to announce...
January 19, 2023
/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to announce that a new therapy to treat rare...
January 19, 2023
/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to announce that a new therapy to treat rare...
January 19, 2023
QINLOCK (ripretinib) now Medsafe approved for GIST patients in NZ QINLOCK now being considered by PHARMAC for reimbursement Data from the INVICTUS Phase 3 study shows QINLOCK reduces risk of disease progression or death by 85%1, 2 SINGAPORE and AUCKLAND,New Zealand, Jan. 20, 2023 /PRNewswire/ --Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to announce that anew therapy to treat rare gastrointestinal stromal tumour (GIST) shown to improve survival has now bee...
January 19, 2023
QINLOCK (ripretinib) now Medsafe approved for GIST patients in NZ QINLOCK now being considered by PHARMAC for reimbursement Data from the INVICTUS Phase 3 study shows QINLOCK reduces risk of disease progression or death by 85%1, 2 SINGAPORE and AUCKLAND,New Zealand, Jan. 20, 2023 /PRNewswire/ --Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to announce that anew therapy to treat rare gastrointestinal stromal tumour (GIST) shown to improve survival has now bee...
January 18, 2023
/PRNewswire/ -- Taiho Oncology, Inc. today announced the publication of results from the pivotal Phase 2 FOENIX*-CCA2 clinical trial of futibatinib in the...
January 18, 2023
/PRNewswire/ -- Taiho Oncology, Inc. today announced the publication of results from the pivotal Phase 2 FOENIX*-CCA2 clinical trial of futibatinib in the...
January 17, 2023
Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene